LYCOS RETRIEVER 
Ebola: Infection
built 200 days ago
There is some evidence that Ebola may benefit from antibody-dependent enhancement of infection through binding of complement component C1q to Ebola-specific IgG and IgM/virus complexes. This C1q/Ab/virus complex is then bound by C1q receptor on susceptible cells. The potential of facilitating ADE may be influenced by antibody titer, in that high levels of antibody may be sufficient to neutralize the virus, whereas a subneutralizing antibody titer may contribute to the possibility of C1q being able to bind an antibody-virus complex, facilitating its uptake into vulnerable cells. It is uncertain how significant a role ADE may play in vivo, but it is an important consideration, particularly with regards to vaccine development.
Source:
The candidate vaccine is synthesized using modified, inactivated genes from Ebola virus. This gives the immune system information about viral structures so that it can mount a rapid defense should the real virus ever be encountered. There is no infectious material in the vaccine, and the virus was not present during any stage of the manufacturing process, notes Barney Graham, M.D., Ph.D., director of the clinical trials unit of the Vaccine Research Center at NIAID. "It is impossible for the vaccine to cause infection," he adds, "because it employs new technology known to safely stimulate broad immune responses."
Source:
One of the scientists performing the necropsies on the infected chimpanzees contracted Ebola. She developed symptoms similar to dengue fever approximately a week after the necropsy and was transported to Switzerland for treatment. After two weeks she was discharged from hospital, and was fully recovered six weeks after the infection.
Source:
It is widely held that robust innate and adaptive responses are both necessary for control and clearance of Ebola infection. The profound impact Ebola infection has on innate immunity has been described above, and those factors in conjunction with specific impairment of the branches of adaptive immunity are important determinants in the pathology of Ebola infection, particularly in the intermediate and end stages of the disease. Early presence of specific anti-Ebola antibodies, and proper functioning of helper and cytotoxic T cells in coordinating cytokine release and antibody switching and clearing Ebola-infected cells are the factors most strongly correlated with increased likelihood of survival from Ebola infection.
Source:
There is no cure for Ebola hemorrhagic virus. Your treatment will include therapy for symptoms you are experiencing, which may include intravenous management of your fluids and electrolytes, oxygen and blood pressure support, and treatment for any complicating infections.
Source:
MORE ABOUT
Infection